Venturing down unexplored paths

<p>Image of a woman dressed in a lab coat, carefully looking into a stethoscope. The surrounding environment indicates she’s in a lab.</p>

Mendus is leveraging its unparalleled expertise in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.

With complementary therapeutic approaches in Phase II clinical development that are based on intratumoral priming and cancer relapse vaccination, the company aims to improve survival outcomes and quality of life for a broad population of cancer patients. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm.

Meet the Management Team

<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Erik Manting

Chief Executive Officer

Ph.D. in Molecular Microbiology and M.Sc. in Medical Biology

Born: 1971

Shares: 277,695

Stock options: 662,666  (LTI 2023/2027)

Experience:
Erik Manting holds a MSc in Medical Biology and a PhD in Molecular Microbiology. He worked for a number of years as a post-doctoral researcher in the field of immunology before making a career switch to banking in 2001. He spent more than 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co. He became CEO of DCPrime BV in 2018 and CEO of Immunicum AB in March 2021, following the merger between both companies. The combined company was renamed Mendus in June 2022.

Ongoing engagementsSupervisory board member Synerkine Pharma BV, Independent Director Transcode Therapeutics Inc.

Learn more
<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Alex Karlsson-Parra

Chief Scientific Officer

M.D., Ph.D. Adjunct Professor in Clinical Immunology, Uppsala University, Sweden

Born: 1950

Shares: 39,124 (private and through related persons’ holdings)

Stock options: 189,333
 (LTI 2023/2027)

Experience: Alex Karlsson-Parra has more than 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Mendus, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical Immunology. In 2014, Dr. Karlsson-Parra was awarded the Athena Prize,  the most prestigious award for clinical research in the the Swedish healthcare community. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.

Ongoing engagements: –

Learn more
<p>Close up portrait of a man looking into the camera with a a neutral face.</p>

Jeroen Rovers

Chief Medical Officer

M.D., Ph.D., Dr. Rovers has a medical degree from Leiden University and a Ph.D. in Surgical Oncology

Born: 1970

Shares: 107,526

Stock options: 331,333 (LTI 2023/2027)

Experience: Jeroen Rovers trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 20 years he worked in different academic institutes and companies, such as Wyeth and Organon and most recently at Kiadis Pharma where he held the role as Chief Medical Officer. Most of the products he worked on are related to oncology, haematology and transplantation.

Ongoing engagements: –

Learn more
<p>Portrait of a woman looking into the camera with a subtle smile.</p>

Lotta Ferm

Chief Financial Officer

Degree in Business Administration and Economics from Högskolan Kristianstad and Växjö University

Born: 1966

Shares: 135,000 (private and through related persons’ holdings)

Stock options: 331,333 (LTI 2023/2027)

Experience: Lotta Ferm has nearly 30 years of finance and controlling experience from a range of corporations including most recently Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. She has held CFO, Head of Finance and Head of Controlling positions consistently over the last decade and led the corporate finance and accounting functions for multiple transitions for dynamic and innovative companies.

Ongoing engagements: –

Learn more
<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Leopold Bertea

Chief Technology Officer

Ph.D. in Chemical Engineering

Born: 1964

Shares: 60,269

Stock options: 331,333 (LTI 2023/2027)

Experience: Leopold Bertea joined Mendus from Cellectis in 2022, a clinical-stage biotechnology company using a proprietary gene-editing platform to develop cell and gene therapies, where he most recently held the position of Senior Vice President Technical Operations Europe and Member of the Cellectis Executive Committee. With previous senior roles at Novartis, LFB Biotechnologies, and LFB’s subsidiary CELLforCURE, Sanofi, and Ciba-Geigy, Dr. Bertea brings a total of 27 years of biopharmaceutical industry experience to Mendus.

Ongoing engagements: –

Learn more

Meet the Board of Directors

<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Sven Andreasson

Chairman since 2024 and 
Board Member since 2020

MSc from Stockholm School of Economics and Business Administration

Born: 1952

Shares: 0

Experience: Sven Andreasson is a Swedish citizen, born in 1952 and resides in Washington DC, US. Sven holds a degree in business administration from Stockholm School of Economics and MBA-educations from IMEDE Lausanne, INSEAD Fontainebleau and Ashridge London. Sven Andreasson has broad experience from biotech and pharmaceutical companies. He was CEO of Active Biotech AB 1999-2008, Beta-Cell NV in Belgium 2008-2012 and Isconova AB 2012-2013 where he initiated and completed a sale of the company in 2013 to the American company Novavax. Sven has also held several senior management positions within Pharmacia in Sweden, Germany, Belgium and France. Previous experience from board assignments includes e.g., TiGenix NV, Belgium, Immunicum AB and Cantargia AB as well as Chairman of Erytech SA, France.

Ongoing engagements: Sven is currently working as Senior Vice President of Novavax with responsibility for Business Development. Board member of Cellastra Inc., US and Erytech SA, France.

Independency: Sven Andreasson is independent in relation to the company, its senior executives and major shareholders.

Learn more
<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Hans Preusting

Board Member since 2021

Ph.D. in Biochemistry and a M.B.A. from the Rotterdam School of Management

Born: 1962

Shares: 10,000

Experience: Hans Preusting has previously served as the Chief Business Officer and interim COO of uniQure. Prior to that he was the VP of Process Development and Manufacturing at AMT, the predecessor of uniQure. Hans now works as an independent consultant for several biotech companies and is co-founder of two biotech start-up companies. He holds two patents and has published over 20 scientific articles. His expertise is focused on business development, product development and manufacturing. He earned a Ph.D. in biochemistry from the University of Groningen, the Netherlands and an M.B.A. from the Rotterdam School of Management, the Netherlands.

Ongoing engagements: Dr. Preusting is currently CEO of Synerkine Pharma B.V. and CDO of DegenRx B.V.

Independency:Hans Preusting is independent in relation to the company, its senior executives, and major shareholders.

Learn more
<p>Close up portrait of a man looking into the camera with a subtle smile.</p>

Dharminder Chahal

Board Member since 2021

Master’s degree in Business Economics, master’s degree cum laude in Aerospace Engineering

Born: 1976

Shares: 264,615

Experience: Dharminder Chahal is currently the CEO and co-founder of SkylineDx, The Netherlands, developing diagnostic tests in oncology. He is also owner and managing director of Exponential BV in which capacity he acts as consultant to Van Herk Investments. Previously he has held various positions in investment banking and asset management including at Kempen & Co and Robeco.

Ongoing assignments: Board member of BioInvent, Ceradis, Medis Medical Imaging, Sensara and Vitalnext as well as advisory board member of BioGeneration Ventures II, Thuja Capital Fund I and Gilde Healthcare Funds II and III.

Independency:Dharminder Chahal is independent in relation to the company and its senior executives, and dependent in relation to the major shareholders.

Learn more
<p>Close up portrait of a woman looking into the camera while smiling.</p>

Helén Tuvesson

Board Member since 2020

MSc, Ph.D. from Lund University

Born: 1962

Shares: 3,200

Experience: Helén Tuvesson is a Swedish citizen, born in 1962 and holds a doctor’s degree in cellular and molecular biology in medical science at Lund University. She has more than 25 years of experience from the pharmaceutical industry in various positions within Pharmacia and Active Biotech, including as Chief Scientific Officer at Active Biotech for 6 years. In this role she was responsible for the operational research activities and the company’s project portfolio in late stage clinical development in neurodegenerative diseases and cancer indications. Since 2017, Helén is the CEO of Active Biotech AB.

Ongoing engagement: CEO, Active Biotech AB

Independency: Helén Tuvesson is independent in relation to the company, its senior executives and major shareholders.

Learn more

Ted Fjällman

Board Member since 2023

Ph.D. in Molecular Biology

Born: 1978

Shares: 0

Experience:
Dr Ted Fjällman has been CEO of Flerie since January 2023, previously having been Partner, Venture Partner and the CEO of portfolio company Prokarium. He is board member of several drug development companies and was the first CEO of NorthX Biologics after Flerie acquired a manufacturing facility from Charles River to set up this CDMO. Ted has previously worked in clinical research and strategy consulting and holds a PhD in Molecular Biology from the University of Guelph, Canada. He has served as committee member of the UK BioIndustry Association (BIA) and on the Management Board of the international Bacterial Vaccines Network (BactiVac). He also co-founded Tekiu, a knowledge transfer broker active internationally. He enjoys travelling, cultural exchanges and languages and splits his time between Switzerland, Sweden and the UK. 

Ongoing engagements:
CEO, Flerie Invest AB.
Board member of NorthX Biologics, Geneos Therapeuitcs, Vitara Biomedical, Amarna Therapeutics, Prokarium, Synerkine Pharma, Alder Therapeutics, XNK Therapeutics, St Andrews Folkestone Ltd and Tekiu Ltd.

Independency: Ted Fjällman is independent in relation to the Company and its senior executives, and dependent in relation to the major shareholder Flerie Invest AB

Learn more

Meet the Scientific Advisory Board

Ada Kruisbeek

Chair of the SAB

Ph.D., Emeritus Professor of Immunology at VU University, Amsterdam

Experience: Ada Kruisbeek, Ph.D. previously served as Chief Scientific Officer at DCprime, which she founded in 2005. She has worked at the National Cancer Institute in Bethesda, USA, and previously held the position of Head of the Department of Immunology at the NKI-AVL (Netherlands Cancer Institute and Antoni van Leeuwenhoekziekenhuis Hospital) in Amsterdam. She is an Emeritus Professor of Immunology at VU University, Amsterdam where she also served as scientific director of the Life Sciences Center and the Technology Transfer Office of the VU.

Learn more

Inge Marie Svane

Member of the SAB

M.D., Ph.D. Professor, Head of the Clinical Cancer Research Program, Faculty of Health Sciences, University of Copenhagen; Director, Centre for Cancer Immunotherapy (CCIT); consultant in Oncology, Herlev University Hospital

Experience: Inge Marie Svane, MD, PhD, joins Immunicum’s Scientific Advisory Board with 25 years of research experience in cancer immunology and immunotherapy. With her focus of expertise on T cell based adoptive cell therapy and other cellular therapies, cancer vaccines and immune regulation, she has greatly contributed to the field of cancer immunotherapy. Since 2001 she has initiated more than 20 Phase I and II immunotherapeutic trials as sponsor or principle investigator and has served as investigator and co-investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of cancer immunotherapy. Dr. Svane also led the establishment and currently serves as Director of the Centre for Cancer Immunotherapy (CCIT), Herlev University Hospital at the University of Copenhagen. Inge Marie has served as Chair of the European Society for Medical Oncology (ESMO) Scientific Committee on Immunotherapy and is author/co-author of more than 170 scientific publications including papers in Clinical Cancer Research, Cancer Research, Blood, Nature Immunology, Nature Biotechnology, Lancet Oncology, Immunology, Journal of Translational Medicine, PLOS ONE and Oncoimmunology, among others.

Learn more

Lewis Lanier

Member of the SAB

PhD, Professor Emeritus in Microbiology and Immunology at University of California, San Francisco (UCSF)

Experience: Lewis Lanier has served as the chair of the Department of Microbiology and Immunology, the co-leader of the Cancer Immunology and Immunotherapy Program at the UCSF’s Comprehensive Cancer Center, and Director of the Parker Institute for Cancer Immunotherapy (PICI). He has published more than 400 scientific articles and is a Senior Editor of the Journal of Experimental Medicine, and has served as an Editorial Board Member of the Journal of Immunology, Annual Review of Immunology, Immunological Reviews, Tissue Antigens, Human Immunology, Immunogenetics, and Immunity. In recognition of his scientific contributions, he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute in New York in 2002, was given the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics in 2005, was elected to the US National Academy of Sciences, in 2010, and was named a Fellow of the American Academy of Microbiology by the American Society for Microbiology and elected to the American Academy of Arts and Sciences in 2011.

Learn more

Sjoerd van der Burg

Member of the SAB

Ph.D., Professor in Experimental Cancer Immunology and Therapy, Department of Medical Oncology, Leiden University Medical Center; Senior Investigator, Oncode Institute, The Netherlands

Experience: Sjoerd van der Burg, PhD, is a Professor in Experimental Cancer Immunology and Therapy at the Department of Medical Oncology of the Leiden University Medical Center and Senior Investigator at the Oncode Institute in The Netherlands. His group performs fundamental, translational, and clinical studies focusing on factors of host-tumor interactions that determine the success and failure of immune system control of cancer. Dr van der Burg has extensive experience in monitoring innate and adaptive immune responses and exploits this to guide the development of cancer therapies. He has a PhD in immunology from Leiden University.

Learn more

Tanja de Gruijl

Member of the SAB

Ph.D., Professor, Translational Tumor Immunology and Fenna Diemer Lindeboom Chair, Amsterdam University Medical Center

Experience:Tanja de Gruijl, PhD, is a Professor of Translational Tumor Immunology and holds a Fenna Diemer Lindeboom Chair at the Amsterdam University Medical Center where she also heads the immunotherapy and immune monitoring lab. Her research ranges from preclinical studies to monitoring of Phase I-III clinical trials and includes topics such as the immune potentiation of tumor-draining lymph nodes and the tumor microenvironment, immunological arming of oncolytic adenoviruses, and nanobody-mediated targeting of Natural Killer T-cell subsets. Dr de Gruijl supervised the research that supported the foundation of DCprime. She has recently been elected to the board of directors of the Society for the Immunotherapy of Cancer (SITC). Dr de Gruijl holds a PhD in tumor immunology from the VU Amsterdam.

Learn more